RxDoctor Payments Data

Shawn Breeding, PA

Physician Assistant · Dayton, OHNPI 1073885216

Payments from drug & device makers

$2,851in general payments, 2019–2025

Across 45 payments — averaging $63.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$594
  • AbbVie$457
  • Axsome Therapeutics, Inc.$451
  • Teva Pharmaceuticals USA, Inc.$282
  • Neos Therapeutics, LP$249
  • Neurocrine Biosciences, Inc.$245
  • plus $573 from 8 others

What the payments were for

  • Food & beverage$2,851100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,851 in reported general payments places this provider in the 90th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$8,646
Medicare patients
14
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$174,097
Invega SustennaPaliperidone Palmitate45$126,585
VraylarCariprazine Hcl61$86,085
RexultiBrexpiprazole23$39,265
Abilify MaintenaAripiprazole13$36,068
PerserisRisperidone11$29,845
Lurasidone Hcl76$27,109
Aripiprazole147$10,548
Quetiapine Fumarate377$5,996
Trazodone Hcl378$3,811
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine53$3,791
Buspirone Hcl229$3,504
Olanzapine90$2,804
Lamotrigine296$2,612
Bupropion XlBupropion Hcl144$2,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$245$174,09720 claims
Johnson & JohnsonInvega Sustenna$31$126,58545 claims
AbbVieVraylar$457$86,08561 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$594$75,33336 claims
Indivior Inc.Perseris$15$29,84511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →